AusperBio

AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137

July 15, 2024

•

Fineline Cube

AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37 million in a Series A financing round. The round was spearheaded by the InnoPinnacle Fund, with additional investments from a consortium that includes Yuanbio Venture Capital, Hankang Capital, Qiming Venture Partners, and Genesis Capital. The…
AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China

July 8, 2024

•

Fineline Cube

AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137 is on track to receive breakthrough therapy designation (BTD) in China for the treatment of chronic hepatitis B virus (HBV). AHB-137 is a highly potent, pan-genotypic antisense oligonucleotide (ASO) that targets all HBV RNA, positioning…

Fineline Info & Tech